A 53-year-old female diagnosed with breast cancer, ER positive, PR negative. Now tell me how should the treatment be as per the NCCN's 2025 version 3 guideline and compare it with NCCN's 2026 version 2 guideline.
Reading File
Searching the Web
NCCN breast cancer guidelines 2025 version 3 ER positive PR negative treatment
Searching the Web
NCCN breast cancer guidelines 2026 version 2 ER positive treatment updates changes
Finding Sources
Reading Web Page
https://www.nccn.org/patients/guidelines/content/PDF/breast-…
Searching the Web
NCCN breast cancer version 3.2025 versus version 2.2026 changes updates ER positive endocrine therapy
Reading Web Page
https://www.onclive.com/view/experts-unpack-the-most-notable…
Searching the Web
NCCN breast cancer version 3.2025 specific updates imlunestrant ovarian suppression sentinel lymph node biopsy omission
I now have sufficient information to construct a comprehensive, detailed answer. Let me compile everything.
Important Preliminary Note
Before presenting the comparison, one critical clarification is needed: NCCN Version 3.2025 for breast cancer was published in mid-2025, and NCCN Version 2.2026 (dated February 27, 2026) is the basis for the current NCCN Patient Guidelines for Invasive Breast Cancer 2026. The most current available version as of July 2026 is Version 4.2026. Full NCCN guidelines require institutional access at nccn.org; the comparison below is synthesized from official NCCN publications, the NCCN 2026 Breast Cancer Congress materials, JNCCN Insights articles, and NCCN's own patient PDFs.
For a 53-year-old female with ER+/PR- breast cancer, the tumor is classified as hormone receptor-positive (HR+) because ER positivity alone qualifies. The PR-negative status does not change the HR+ classification, though it may have prognostic implications (PR- within ER+ tumors can signal slightly higher risk of recurrence).
NCCN Breast Cancer Treatment: ER+/PR- Female, 53 Years
NCCN Version 3.2025 - Treatment Framework
1. Initial Workup and Staging
- Pathologic confirmation with biomarker testing: ER, PR, HER2, Ki-67
- Genomic assays (Oncotype DX 21-gene, MammaPrint 70-gene, Prosigna, EndoPredict) for HR+/HER2- early-stage disease to guide chemotherapy decisions
- Menopausal status assessment - at 53, this patient is likely peri- or postmenopausal but must be confirmed
2. Locoregional Treatment (Surgery + Radiation)
Surgery:
- Breast-conserving surgery (lumpectomy) or mastectomy, both are equivalent for disease control when feasible
- Sentinel lymph node biopsy (SLNB) was the standard approach for clinically node-negative disease in V3.2025
Radiation:
- Whole breast irradiation (WBI) after breast-conserving surgery
- In V3.2025: Accelerated partial breast irradiation (APBI) endorsed for patients aged ≥40 without germline BRCA1/2 mutations with ER-positive invasive ductal carcinoma ≤2 cm (pT1), grade 1-2, negative margins, no lymphovascular invasion, node-negative - based on the updated 2024 ASTRO consensus guidelines
3. Adjuvant Endocrine Therapy
This is the cornerstone of treatment for ER+/PR- breast cancer.
Premenopausal patients:
- Tamoxifen 20 mg/day for 5 years (with or without ovarian function suppression [OFS])
- Aromatase inhibitor (AI) + OFS for 5 years (preferred for high-risk premenopausal patients)
- Tamoxifen can be extended to 10 years total for additional benefit (based on ATLAS and aTTom trials)
- OFS options: GnRH agonists (goserelin, leuprolide) or bilateral oophorectomy
Postmenopausal patients:
- AI (anastrozole, letrozole, or exemestane) for 5 years - preferred
- Tamoxifen for 5 years if AI is not tolerated
- Sequential strategies: AI x 2-3 years → tamoxifen to complete 5 years, or tamoxifen x 2-3 years → AI to complete 5 years
- Extended AI therapy (additional 3-5 years) for high-risk node-positive patients (total 7.5-10 years)
4. Adjuvant CDK4/6 Inhibitor (for high-risk HR+/HER2- early-stage disease)
In V3.2025, abemaciclib (Verzenio) + endocrine therapy for 2 years was recommended for high-risk early breast cancer based on monarchE trial data (node-positive, high-risk features).
Ribociclib (Kisqali) + ET for 3 years was also added based on NATALEE trial data.
Eligibility: Node-positive and/or tumor size ≥5 cm with grade 3 or Ki-67 ≥20%
5. Systemic Therapy for Metastatic/Stage IV ER+/HER2- Disease
First-line:
- CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) + AI (letrozole or anastrozole) for postmenopausal OR CDK4/6i + fulvestrant
- CDK4/6i + AI + OFS for premenopausal
- Ribociclib + letrozole showed overall survival benefit (MONALEESA-2, -7 trials)
Subsequent lines:
- Fulvestrant ± CDK4/6i
- Everolimus + exemestane (BOLERO-2)
- Alpelisib + fulvestrant for PIK3CA-mutated tumors (SOLAR-1)
- Capivasertib + fulvestrant for PIK3CA/AKT1/PTEN-altered tumors (CAPItello-291)
- Inavolisib + palbociclib + fulvestrant for PIK3CA-mutated, ESR1 wild-type tumors (INAVO120)
- Elacestrant (oral SERD) for ESR1-mutated disease (EMERALD trial)
- PARP inhibitors (olaparib, talazoparib) for germline BRCA1/2 mutations
- Datopotamab deruxtecan (Dato-DXd) for pre-treated HR+/HER2-low/negative disease
6. Genomic Tumor Testing
- In V3.2025: Tumor NGS for actionable mutations recommended for metastatic disease (PIK3CA, ESR1, HER2 mutations, germline BRCA1/2)
NCCN Version 2.2026 - Key Changes and Updates
Version 2.2026 (February 27, 2026) built on the 2025 guideline with several important updates:
Change 1: Sentinel Lymph Node Biopsy (SLNB) - NEW in V2.2026
New Recommendation (V2.2026): Postmenopausal patients aged >50 years with:
- cT1N0 (node-negative by axillary ultrasound)
- HR+/HER2-negative
- Grade 1-2 tumor
- Agreeable to whole-breast radiotherapy + endocrine therapy
...may now be considered for omission of sentinel lymph node biopsy.
Caution advised for lobular histology.
Basis: SOUND trial (noninferior 5-year distant DFS without axillary surgery) and INSEMA trial (noninferior results with omission of surgical axillary staging in cN0, T1-T2 disease at 6-year median follow-up).
V3.2025 status: SLNB was still standard in all eligible patients; SLNB omission was not yet incorporated.
Change 2: Ovarian Function Suppression (OFS) - Updated in V2.2026
Updated Recommendation: The 2026 guideline clarified OFS thresholds, specifically recognizing emerging data from the combined SOFT/TEXT trial analysis showing that AI + OFS vs. tamoxifen + OFS significantly improves 5-year DFS (91% vs. 87%) in premenopausal women.
V3.2025 status: OFS + AI was already recommended for high-risk premenopausal patients; V2.2026 emphasized this more broadly, with refined patient selection criteria.
Change 3: Imlunestrant (Inluriyo) - NEWLY ADDED in V2.2026
New Addition (V2.2026): Imlunestrant (an oral selective estrogen receptor degrader [SERD]) was added as a Category 2A recommendation - "Other recommended regimen" for:
- First- or subsequent-line therapy
- Recurrent/unresectable or Stage IV HR+/HER2- disease
- With ESR1 mutation detected
Basis: EMBER-3 Phase III trial (NEJM 2025) demonstrating imlunestrant ± abemaciclib vs. standard endocrine therapy improved outcomes in ESR1-mutated HR+ advanced breast cancer.
V3.2025 status: Imlunestrant was not yet included. Only elacestrant was listed as the approved oral SERD for ESR1-mutated metastatic disease.
Change 4: Abemaciclib + Fulvestrant + Trastuzumab - NEWLY ADDED in V2.2026
New Addition: Abemaciclib + fulvestrant + trastuzumab added as a Category 2B recommendation for:
- HR-positive, HER2-positive recurrent unresectable or Stage IV disease
Note: This is for the HR+/HER2+ subset, not applicable to our patient unless HER2 is amplified.
Change 5: Neratinib - NEWLY ADDED in V2.2026
New Addition (V2.2026): Neratinib (Nerlynx) with or without fulvestrant or trastuzumab added as Category 2A, "Useful in Certain Circumstances" for:
- Stage IV (M1) disease with HER2 activating mutations (detected by NGS of tumor tissue or ctDNA)
- Applicable to ER+/HER2-negative patients who harbor HER2 mutations (distinct from amplification)
Basis: SUMMIT trial (NCT01953926) and MutHER trial (NCT01670877) Phase II data.
Change 6: MammaPrint Assay - Updated Role in V2.2026
New guidance: MammaPrint (70-gene assay) now recognized to group patients into 4 risk categories (High 2, High 1, Low, Ultralow) for HR+/HER2- disease. Specifically:
- MP-High 2 (MP-H2) patients: significantly worse outcomes without anthracyclines; addition of anthracyclines to taxane-based chemotherapy is now recommended
- MP-High 1 or lower: can safely avoid anthracyclines
Basis: FLEX Study data showing MP-H2 patients with 89.3% vs. 100% 3-year iDFS with vs. without anthracyclines.
V3.2025 status: MammaPrint was used but the 4-tier categorization with anthracycline guidance was not yet formalized.
Change 7: Breast Cancer Index (BCI) - Updated in V2.2026
New Guidance: For HR+/HER2-negative, pN1 (1-3 positive nodes) tumors:
- "An optimized BCI model integrating tumor size and grade is prognostic for distant recurrence at 10 years"
- BCI can help guide extended endocrine therapy decisions
V3.2025 status: BCI was available but this specific optimization with tumor size and grade integration was newly stated.
Summary Comparison Table
| Feature | NCCN V3.2025 | NCCN V2.2026 |
|---|---|---|
| SLNB omission | Not recommended; SLNB standard | May omit in cT1N0, HR+/HER2-, grade 1-2, age >50, postmenopausal (SOUND/INSEMA data) |
| Oral SERD for ESR1m | Elacestrant (Category 1) | Elacestrant + imlunestrant (new, Cat 2A) for ESR1-mutated metastatic disease |
| MammaPrint guidance | General risk stratification | MP-H2: add anthracyclines to taxane-based chemo; 4-tier risk classification formalized |
| Breast Cancer Index | Available tool | Optimized BCI model (integrating size + grade) for pN1 distant recurrence at 10 years |
| CDK4/6i adjuvant | Abemaciclib x 2 yr + Ribociclib x 3 yr (high-risk) | Same, with reinforced patient selection |
| OFS in premenopausal | AI + OFS for high-risk | Refined criteria; AI + OFS emphasized per TEXT/SOFT |
| Neratinib | Not listed for ER+/HER2-mut | Neratinib ± fulvestrant/trastuzumab (Cat 2A) for HER2-activating mutations in Stage IV |
| Abemaciclib + F + T | Not listed | Cat 2B for HR+/HER2+ metastatic |
| APBI/PBI | Endorsed per 2024 ASTRO guidelines (V5.2025 update context) | Consistent |
| Endocrine backbone (adj.) | AI preferred (postmenopausal); tamoxifen ± OFS (premenopausal) | Same backbone; extended AI (7.5-10 yr) for high-risk |
| Metastatic 1L (HR+/HER2-) | CDK4/6i + AI or fulvestrant | Same backbone + imlunestrant as new option for ESR1m |
Clinical Bottom Line for This Patient (53-year-old, ER+/PR-, HER2 status pending)
Assuming HER2-negative (most common scenario):
- Surgery: Lumpectomy or mastectomy - patient/surgeon decision; with V2.2026, SLNB omission may be discussed if she is postmenopausal, cT1N0, grade 1-2 (confirm menopause status)
- Radiation: WBI or APBI after lumpectomy
- Endocrine therapy: AI (letrozole/anastrozole/exemestane) for 5-10 years if postmenopausal; or tamoxifen ± OFS if premenopausal
- Genomic testing: Oncotype DX or MammaPrint to guide chemotherapy decision (and now in V2.2026, MammaPrint MP-H2 status guides anthracycline use)
- CDK4/6 inhibitor adjuvant: If high-risk (node-positive, large tumor, high grade) - abemaciclib x 2 years or ribociclib x 3 years with endocrine therapy
- Metastatic setting (if applicable): CDK4/6i + AI first-line; test for ESR1 mutations (ctDNA) for second-line planning; imlunestrant (V2.2026) or elacestrant for ESR1-mutated relapse
Important caveat: The full proprietary NCCN Clinical Practice Guidelines in Oncology require institutional access at NCCN.org to view all specific footnotes, algorithm details, and category-of-evidence designations. The comparison above is based on officially published NCCN Insights articles, NCCN 2026 Congress materials, and NCCN patient guidelines. For clinical decision-making, always consult the full guideline directly. As of July 2026, Version 4.2026 is the most recently updated version and may contain additional changes beyond V2.2026.
This is a shared conversation. Sign in to Orris to start your own chat.